GC
KDNY

Guggenheim Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Guggenheim Capital’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,750
Closed -$298K – 1948
2023
Q2 		$298K Buy
+7,750
New +$199K ﹤0.01% 1664

Guggenheim Capital's KDNY Position: Q3 2023 in Review

Guggenheim Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 7,750 shares — an estimated $298K sold.

Guggenheim Capital first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $298K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Guggenheim Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Guggenheim Capital sold 7,750 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $298K.
  • Guggenheim Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Guggenheim Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $298K in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Guggenheim Capital's 13F filing for Q3 2023, filed 14 Nov 2023.